Skip to main content
. Author manuscript; available in PMC: 2016 Jan 7.
Published in final edited form as: Lab Chip. 2015 Jan 7;15(1):301–310. doi: 10.1039/c4lc00866a

Figure 1. In vivo anti-angiogenesis application and microfluidic assay.

Figure 1

(A) Potential anti-angiogenic therapeutic application in cancer treatment in vivo. (B) Schematic view of the QMAS for screening anti-angiogenic therapeutic drugs. (C) Significant parts of the QMAS are: (1) 3D hydrogel scaffolds in gel cages (fourteen) mimic the extracellular matrix (ECM) in vivo, (2) confluent endothelial cell (ECs) monolayers in the cell culture channels (eight) mimic pre-existing blood vessels in vivo, (3) VEGF-supplemented media in conditioned media channels (seven) mimic the presence of growth factors secreted by tumor in vivo, and (4) bortezomib-supplemented media with various concentrations in the cell culture channels (eight) mimic the introduction of anti-angiogenesis drugs in vivo via the circulation.